The cost-effectiveness acceptability frontier depicts the strategy with the
highest expected net benefit for a given willingness to pay threshold. The no
vaccination strategy has the highest expected net benefit at values of
≤$35,000/QALY, PCV13 substituted for PPSV23 in current recommendations is
favored from $40,000-50,000/QALY, and PCV13 at ages 50 and 65 is favored at
higher willingness to pay thresholds >$50,000/QALY.